MedTrace Logo

A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

NCT05144139 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2022-12-28

No results posted yet for this study

Summary

This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.

Conditions

  • COVID-19 Pandemic

Interventions

BIOLOGICAL

COVID-19 mRNA vaccine

Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval

Sponsors & Collaborators

  • Stemirna Therapeutics

    lead INDUSTRY

Principal Investigators

  • Mayfong Mayxay, professor · Mahosot Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-03
Primary Completion
2022-08-28
Completion
2022-11-11

Countries

  • Laos

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05144139 on ClinicalTrials.gov